1347721-40-7

Basic information

• Product Name: C₁₉H₂₀BrN₃O₂
• Synonyms: C₁₉H₂₀BrN₃O₂
• CAS NO: 1347721-40-7
• Molecular Weight: 402.291
• Mol File: 1347721-40-7.mol

Chemical Properties

• CAS DataBase Reference: C₁₉H₂₀BrN₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₉H₂₀BrN₃O₂(1347721-40-7)
• EPA Substance Registry System: C₁₉H₂₀BrN₃O₂(1347721-40-7)

Safety Data

• Hazardous Substances Data: 1347721-40-7(Hazardous Substances Data)

Upstream product

• 861106-92-5 (2-amino-6-bromophenyl)methanol 
• 1347720-60-8 4-chloro-6-n-propyl-7-methoxy-quinazoline 

Relevant articles and documents

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF

At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.